471 The mechanisms by which SGLT2 inhibitors treat heart failure include lowering blood glucose levels by inhibiting the SGLT2 protein in the renal tubules and reducing glucose reabsorption in the tubules
Studies in humans should be done (42, 43) ( Table 1 )
However, theyre not completely risk-free
Most notably, the top causes of human death, heart disease, diabetes, kidney disease, liver inflammation (fatty liver) but also improving joint issues that can be caused by excess weight, aging and inactivity including back, hip and knee pain and surgeries
Sharma RK, Vittetoe KL, Barna AJ, et al
In addition to these benefits, clinical trials have shown that the medication may improve cardiovascular risk factors and non-alcoholic fatty liver disease